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ABSTRACT
Introduction: Vitamin D is related to resistance to
chronic diseases, physiological parameters and
functional measures. All of these relationships
underscore the potential benefits of cholecalciferol or
D3 (nutritional vitamin D) in cancer. This is the first
study designed to obtain conclusive evidence on the
effect of cholecalciferol in advanced patients with
cancer. The main goal is to assess its effects on the
patient’s perceived quality of life. Cholecalciferol’s
impact on fatigue and physical performance, as well as
its cost utility, will also be assessed.
Methods and analysis: A randomised triple-blind
phase II/III placebo-controlled multicentre trial has
been designed. Patients satisfying the inclusion and
exclusion criteria will be randomly assigned to receive
cholecalciferol or placebo. Eligible patients will be
adults with a locally advanced or metastatic or
inoperable solid cancer in palliative care, who have
given signed informed consent and have matched
inclusion and exclusion criteria. The randomisation will
be based on a computer-generated procedure and
centralised by the pharmacy service of the coordinating
centre. The assigned treatment will be administered by
the hospital’s pharmacy to conceal group allocation for
patients and healthcare providers. Cholecalciferol
(4000 IU/day) or placebo, starting at day 15 and
continuing up to day 42, will be added to palliative care
treatment. Outpatient visits will be scheduled every
14 days.
Ethics and dissemination: Ethical approval was
received from the Medical Ethical Commitee of the
HUAV (CEIC-1169). Participants and their families will
receive the research findings which will also be
disseminated on local and national media, presented at
national and international meetings of the specialty,
and published in peer-reviewed scientific journals.
Trial registration number: EudraCT: 2013-003478-29.
INTRODUCTION
Background and rationale
Cancer-related fatigue is the most common
symptom in patients in palliative care with an
overall prevalence of 90% at terminal stages.1
However, cancer-related fatigue cannot be
easily diagnosed, since it may be masked by
pain, dyspnoea or nausea.2 It often becomes
apparent once it compromises basic daily life
activities.3 Additionally, there are also subject-
ive, psychological and emotional compo-
nents of the impact of lack of strength on
each individual, which can be appropriately
assessed by currently available questionnaires
which measure the patient’s perception of
the impact of fatigue on his/her quality of
life.4 5
The pathogenesis of cancer-related fatigue
is multicausal and involves physiological and
biochemical disorders directly associated
with tumour progression, severe adverse
effects resulting from cancer treatment, as
well as physical and psychological stress,
anaemia, lack of exercise, chronic pain and
severe uncontrolled symptoms.6 7
At present, a variety of interventions have
been studied with reportedly small but sig-
niﬁcant beneﬁts such as drug therapy,8–10
which are not free of adverse effects.
Psychosocial and physical interventions on
fatigue intensity are also available for patients
with cancer.11 However, in patients in pallia-
tive care, recommendations for therapy are
scarce. Functional rehabilitation12 should be
Strengths and limitations of this study
▪ At least a clinically relevant improvement in the
quality of life is expected for oncological patients
with no possibility of curable treatments.
▪ It is a multidisciplinary approach to patient care
which includes coordination with physiatrists in
functional rehabilitation.
▪ Cost utility analysis of vitamin D supplementation
will allow informed decision-making.
▪ Potential limitations are that the amount of sun
exposure, although expected to be low for
patients with advanced cancer in palliative care,
has not been taken into account.
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tailored to each patient to help maintain a relatively
active daily life. The goal is not to recover a speciﬁc level
of activity, but to maintain physical endurance so that
rest or inactivity will not reduce muscle reserve.
Vitamin D is a fat-soluble vitamin present in only a few
foods, but which can be obtained from sun exposure
and supplements in its biologically inert form. It must
undergo two hydroxylations in the body for activation.
First, the liver converts vitamin D to 25-hydroxyvitamin
D (25(OH)D), and afterwards the physiologically active
1.25-dihydroxyvitamin D (1.25(OH)2D) is produced
mainly by the kidneys.
A recently published review13 supports numerous
reports delineating the multiple mechanisms underlying
vitamin D prosurvival actions experimented with at the
laboratory. Their ﬁndings show that vitamin D deﬁciency
results in a defective control of: (1) Cell growth causing
hyperproliferative disorders, genomic instability, Tumour
necrosis factor Alpha Converting Enzyme (TACE)-driven
metastasis, exacerbated growth and immune escape; and
accelerated progression of cancer lesions;14–17 (2) DNA
repair mechanisms causing age-associated disorders and
resistance to therapy in cancer;16 18 (3) Muscular weak-
ness and impaired neuromuscular function;19 20 (4)
Musculoskeletal pain derived from cancer treatment;21
(5) The immune system causing increased antigenicity in
antigen presenting cells, reduced content of T-regulatory
lymphocytes, systemic inﬂammation and multiple organ
damage, as well as a higher propensity for autoimmune
disorders;15 19 (6) The integrity of the FGF23/klotho
responsible for the antiageing properties of klotho in the
kidneys, in protecting the vasculature from atheromatosis
and calciﬁcation, and as a tumour suppressor and
protector from the onset of resistance in cancer treat-
ment;22–24 (7) The renin-angiotensin system to prevent
hypertension, renal and cardiovascular damage due to
excessive oxidative stress;25 26 (8) Acquisition of athero-
thrombotic phenotype of circulating monocytes-
macrophages and increased severity of atherosclerotic
lesions;27 (9) Podocyte function to protect from protein-
uria and proteinuria-induced cardiovascular lesions.28 29
When no curable treatment is possible, palliative care
is directed towards minimising symptoms, relieving suf-
fering and bringing patients to the best possible
health-related quality of life (HRQoL). Avoiding the tox-
icity associated with some palliative treatments is a must
in these patients. There is an urgent need to develop
new interventions in this population based on current
evidences, namely: (1) The strong epidemiological asso-
ciation between vitamin D deﬁciency and the high risk
of mortality from all causes in the general population15
and speciﬁcally from cancer;30 31 (2) The high fre-
quency of vitamin D deﬁciency in patients with cancer,
estimated to be between 47%32 and 88%;33 (3) The
anticancer, antiageing, antipain, immunomodulatory
and the protective renal, cardiovascular and neuromus-
cular properties of a normal vitamin D status;15 19 34 35
and (4) The signiﬁcant 11% reduction in all cause
mortality estimated for D3 by combining all randomised
controlled trials.30 We present a clinical trial designed to
obtain, for the ﬁrst time, evidence-based recommenda-
tions on the efﬁcacy of vitamin D3 supplementation, a
safe, non-costly therapeutic strategy, in improving phys-
ical performance, decreasing fatigue and increasing
HRQoL in patients with advanced cancer in palliative
care.
OBJECTIVES
The primary objective of this study is to evaluate the efﬁ-
cacy of the administration of vitamin D3 to enhance
patient-reported HRQoL.
The secondary objectives of this study are: (1) To
evaluate the efﬁcacy of the administration of vitamin D3
for enhancing physical performance, decreasing per-
ceived fatigue and achieving serum levels of 25(OH)D
above 30 ng/mL; (2) To evaluate the effect on tumour
biomarkers; (3) To explore the relationship between
vitamin D treatment compliance and 25(OH)D levels;
(4) To explore the relationship between 25(OH)D levels
and renal function; (5) To explore the dose–response
relationship in the group of patients with vitamin D3 for
the main outcome; (6) and to assess the cost utility of
the proposed administration of vitamin D3.
METHODS AND ANALYSIS
The tolerable upper intake level (UL=4000 IU/day or
100 µg/day) has already been established by the
European Food Safety Authority for the adult popula-
tion.36 However, there is a need for a proof of concept
trial to be conducted in patients with advanced cancer
in palliative care to gain preliminary data on the safety
and efﬁcacy of high doses (at UL) of vitamin
D. Therefore, a phase II proof of concept study is
planned to obtain reliable data to support a phase III
conﬁrmatory trial, within a randomised controlled trial
with a placebo two-stage adaptive design.
Trial design
A randomised triple-blind phase II/III placebo-controlled
multicentre trial has been designed. The randomisation
will be based on a computer-generated procedure centra-
lised by the pharmacy service of the coordinating hospital
in order to ensure the required treatment allocation con-
cealment. Serum levels of vitamin D will be not available
for the patients or their physicians to preserve treatment
allocation concealment. Randomisation will be stratiﬁed
by primary solid tumour type in a 1:1 ratio. In a proof of
concept trial (phase II or stage 1), patients will be
assessed after the ﬁrst 14 days of treatment about self-
perceived changes in HRQoL. The study includes a ﬁrst
interim analysis similar to a futility test to discontinue the
trial, and reject vitamin D3, if no better outcome is
obtained when compared to the placebo group.
Otherwise, it will continue to Phase III (stage 2), which is
planned to establish the efﬁcacy in improving and
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maintaining HRQoL as well as the safety of the treatment
with UL of vitamin D over placebo for 28 days (till day 42
from enrolment). This study will assess the efﬁcacy of
vitamin D when administered in combination with the
usual palliative care and functional rehabilitation.
Study setting
Phase II of the study will take place at Hospital
Universitari Arnau de Vilanova (Lleida, Spain). For
phase III of the study, three additional Spanish hospitals,
Duran i Reynalds (Barcelona), La Paz (Madrid) and
Virgen de la Macarena (Sevilla), will participate.
Patients
Eligible patients will be adults with a locally advanced or
metastatic or inoperable solid cancer in palliative care on
signed informed consent. Exclusion criteria will be
having a Karnofsky <30%, being pregnant or breastfeed-
ing females, undergoing severe liver or renal (glomerular
ﬁltration rate <60 ml/min) failure, having a cognitive
deterioration (more than 5 mistakes in the Pfeiffer test),
suffering from signiﬁcant pain, dyspnoea, nausea or
vomiting (more than 6 out of 10 in the corresponding
Numerical Rating Scale 0:10), hypercalcaemia
(> 10.5 mg/dL), having received chemotherapy or radi-
ation therapy within the past 3 weeks prior to inclusion,
or having the possibility of initiating a new cycle of
chemotherapy or radiation therapy within a period of
6 weeks after their inclusion date.
A prescreening day is scheduled for each adult patient
with a locally advanced or metastatic or inoperable solid
cancer in palliative care who did not present any known
reason to be excluded. On that day, a blood test will be
ordered (since results should be available on the screen-
ing day for the complete assessment of exclusion cri-
teria) and a visit with the physical rehabilition medical
doctor will be scheduled for the same day.
On the screening day, those patients satisfying inclu-
sion and exclusion criteria will be provided with com-
plete information about the study and enrolled into the
study pon signed informed consent.
Intervention
Vitamin D3 supplements of 4000 IU/day (UL) or
placebo will be added to palliative care treatment on day
14 after enrolment and continued up to day 42.
Outpatient visits will be scheduled every 14 days.
Supportive evidence for the UL established dose36 is
provided by randomised controlled studies in which this
quantity or higher was administered to various popula-
tion groups for up to 12 months without evidence of
persistent hypercalcaemia or hypercalciuria.
Palliative care treatment will be standardised among
participating physicians to ensure comparable proce-
dures on symptoms control (pain, nausea, vomiting,
constipation, diarrhoea, lack of appetite, shortness of
breath, cough and dry mouth).
Functional rehabilitation will be coordinated by the
rehabilitation doctor at each participating hospital from
day 0. On that day, there will be an evaluation of the
clinical and functional status (weakness, effort tolerance,
mobility, functional performance and independence in
activities of daily living), neuro-orthopaedic disorders,
orthopaedic aids necessary to improve the functionality
and individualised physical therapy to perform. Three
additional sessions will be scheduled before day 14 to
work in the following basic protocols: Assisted and free
active physical therapy; Respiratory physiotherapy;
Rehabilitation of trunk balance in sitting and standing;
Re-education in walking; Energy saving measures, and
teaching family involvement. Any requirement for add-
itional measures of rehabilitation will be speciﬁcally
noted. Leaﬂets containing advice and recommended
exercises for functional rehabilitation will be provided to
all participating patients and their families.
OUTCOMES
Primary outcome
Change in patient self-reported HRQoL is the primary
outcome. It will be assessed using the European
Organisation for Research and Treatment of Cancer
(EORTC) QLQ-C15-PAL,37 a questionnaire developed
for patients with cancer in palliative care. It includes
rates on: pain, physical function, emotional function,
fatigue, global health status/quality of life, nausea/
vomiting, appetite, dyspnoea, constipation and sleep. Its
scale rating global health status/quality of life using a num-
bered scoring scale from 1 or very poor to 7 or Excellent is
the primary outcome. An anchor question approach is
included in order to establish ranges of scores reﬂecting
patient self-assessment of changes in perceived HRQoL
(as an approach to minimal important difference
assessment).
Since patients with advanced cancer in palliative care
can undergo rapid health deterioration (within a few
days), primary as well as secondary outcomes will be
recorded at baseline and on the allocation day (14 days
after enrolment) in order to assess intrapatient variabil-
ity occurring before any intervention. After starting the
intervention, primary and secondary outcomes will be
collected on days 28 and 42 from enrolment day (after
14 days and 28 days of taking vitamin D or placebo).
Secondary outcomes
Change in cancer-related fatigue is the second most
important outcome, and will be assessed with the fatigue
subscale of the Functional Assesment of Cancer
Therapy:Fatigue (FACT-F) questionnare.38 FACT-F is a
widely used 13-item fatigue subscale where each item is
a ﬁve-point Likert self-report scale ranging from 0=‘not
at all’ to 4=‘very much so’. The total score varies from
0=‘worst condition’ to 52=‘best condition’.
Change in functional capacity is another important
secondary outcome and will be assessed using the
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Barthel Scale,39 an ordinal scale that measures perform-
ance in activities of daily living, as well as the Karnofsky
and the Palliative Performance Scale (PPS) scores,40 41
which are used to quantify patients’ performance status.
All of them provide a score from 100 to 0, where 100
indicates no evidence of disease (normal performance)
and 0 indicates death.
Other secondary outcomes include changes in serum
levels of 25-hydroxyvitamin D, changes in tumoural bio-
markers, adherence to the randomised intervention
(deﬁned by the proportion of compliance with the ran-
domised intervention out of the total 28 days), renal
function and cost utility analyses. Utilities will be based
on the patient self-reported HRQoL measured by
EuroQoL (EQ-5D; 3 L). This questionnaire assesses ﬁve
dimensions (mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression) to deﬁne the health state
of patients. Each health state will be translated in the
corresponding valuation by applying the Spanish
general population utility weights, resulting in valuations
from 1 (optimal health) through 0 (as bad as death) to
negative values (worse than death). Direct costs will be
collected in both groups.
Sample size
The research team considers that a 15% difference is
clinically relevant and that differences below 15% will
not sufﬁce to demonstrate the clinical signiﬁcance of
the effect of supplementation with vitamin D on quality
of life. Therefore, this study is designed to detect differ-
ences of 15% or more in the proportion of patients with
improved HRQoL between the groups. Error probabil-
ities of α and β to 0.05 and 0.2, respectively, for a unilat-
eral contrast with a 1:1 allocation are ﬁxed for sample
size calculations.
The phase II sample size is designed to control early
stopping probability based on the exact binomial distri-
bution (Simon, 1989) on optimal two-stage designs and
ﬁxed to at least 28 patients per group (optimal design
for the ﬁrst stage). The trial will be stopped if the
number of patients that improve is not higher in the
intervention group than in the control group.
The total sample size for this study (adding phases II
and III) is computed as the minimal number of patients
per group to detect differences from 15%, even in the
case of maximal requirements that would be having pro-
portions of improvement in HRQoL close to 50%.
Therefore, with proportions of improvement in HRQoL
of 42.5% for the placebo group and 57.5% for the
vitamin D group, and using the same error probabilities
in a unilateral contrast, a minimum of 137 patients per
group (a total of 274 patients enrolled) are estimated as
the minimum sample size required by applying the arcsi-
nus approximation. Since twice this improvement could
be observed in the vitamin D group, an interim analysis
is scheduled at the end of treatment for the ﬁrst 43
patients per group (phase II patients included) in order
to minimise the number of patients in the placebo
group. If the difference in the proportion of patients
with minimally improved HRQoL is twice the expected
15% in favour of vitamin D3, the trial will be stopped for
ethical reasons for the beneﬁt of the patients in the
placebo group. In other words, the second interim ana-
lysis is planned with a stopping rule so that if the
improvement difference is 30% or greater, all the partici-
pants will beneﬁt. Figure 1 summarises this study design.
Assignment of interventions
The randomisation process will be centralised at the
Pharmacy Service of the Hospital Universitari Arnau de
Vinalova. The Pharmacy Service will be the responsible
for randomising and blindly assigning vitamin D3 or
placebo to each patient, stratiﬁed by the primary
tumour and blocking it to ensure the same number of
patients in each intervention. Drug or placebo formula-
tion, labelling and allocation will be performed by the
pharmacist, who will create an identiﬁer for each
patient, independently from the order of entry into the
study. The matching of each patient identiﬁer with its
allocated intervention will be saved in an independent
database for the exclusive use of the pharmacist or the
External Safety Monitoring Committee until the end of
the study.
Data collection and management
Figure 2 summarises the data collection and manage-
ment description that is detailed below.
Data collected exclusively at baseline (day 0)
The inclusion and exclusion criteria checklist and base-
line information will be also collected including sociode-
mographical data (age, sex, education), anthropometric
data (height), clinical data (primary tumour, stage and
treatment), as well as treatments that may interact with
vitamin D (antiepileptics, antihypercholesterolaemic,
certain diet drugs and corticosteroids).
Data collected at all visits (days 0, 14, 28 and 42)
Collection will include: anthropometric data (weight,
body mass index, triceps skinfold); palliative care treat-
ments (cachexia, pain,...); functional capacity (Barthel,
Karnofsky, PPS); cancer-related fatigue (FACT-F
Figure 1 Trial design.
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subscale); and quality of life (EORTC QLQ C15 PAL
and EQ-5D). Biochemical data will be separated into
one part available during the study for the patient and
the physician (PCR, total protein, serum albumin, trigly-
cerides and cholesterol (total, low-density lipoprotein,
high-density lipoprotein)) and another available during
the study only for the external Data Monitoring
Committee (25-hydroxyvitamin D, serum calcium and
urinary calcium).
Data collected in the postallocation visits (days 28 and 42)
Patient assessment of change from the start of treatment
will be collected in response to the question: Please indi-
cate whether there has been any change in your health
related quality of life from the start of treatment by
choosing one of the following options: −3, very much
worse; −2, much worse; −1, slightly worse; 0, no change;
1, a little better; 2, much better; 3, very much better. An
at least minimal improvement is deﬁned for patients
with an answer from 1 to 3 to this question.
Reported compliance per day starting on day 15 will
be also collected.
Most people are not expected to suffer from any side
effect, unless they take more than the prescribed
amount of vitamin D. Hypercalcaemia and patient
assessment of weakness, fatigue, drowsiness, headache,
loss of appetite, dry mouth, metallic taste, nausea or
vomiting are the adverse events listed in the bibliog-
raphy. Adverse events will be collected using an ordinal
scale of four categories for each one: ‘No (0 points)’,
‘Mild (1 points)’, ‘Moderate (2 points)’ and ‘Severe
(3 points)’. All adverse events happening postinterven-
tion (from 15th to 48th day) will be recorded through-
out the study, registering: the adverse event name,
starting and ending dates, frequency, severity, intensity,
relationship to study drug, action taken and resolution.
Any suspected unexpected serious adverse reaction
(SUSAR) will be reported to the Spanish Agency
(AEMPS). An SUSAR is deﬁned as any adverse reaction
to vitamin D which shows a reasonably and unexpected
causal relationship, whose nature, severity or outcome is
not consistent with the summary of the characteristics of
the technical data and that produces death, endangers
the patient’s life immediately, produces a persistent or
signiﬁcant disability, requires or prolongs hospitalisation,
or becomes a signiﬁcant danger that is comparable to
the above criteria.
Statistical analysis
For the ﬁrst interim analysis, only the number of
patients with at least minimally improved HRQoL will be
compared, with no statistical test to base the decision to
stop. For the second interim analysis, a difference
between response rates of 30% or higher will be used to
make the decision to stop. At the end of the study, a
descriptive univariate analysis of each group will be per-
formed, followed by a comparison between groups to
check if randomisation produced comparable groups in
each potential confounder. Bivariate analyses will use
the Mann-Whitney or χ2 test for quantitative or qualita-
tive variables, respectively. In case of differences, analysis
of minimally improved HRQoL by logistic regression will
be performed adjusting for them. For differences
between groups in longitudinal measurements (such as
chemistries), linear and non-linear mixed-effect models
will be used. Additionally, for the intervention group
(patients treated with vitamin D), longitudinal measures
of serum vitamin D and renal function will be related by
ﬁtting mixed effects linear models. Main outcomes will
be analysed by intention to treat. A longitudinal analysis
of treatment compliance (cumulative dose in both
periods of 14 days) will be performed in relation to
serum vitamin D levels as well as an analysis per protocol
to look at dose–response effects. Finally, a cost utility
analysis of the intervention with cholecalciferol will be
performed. For each patient, quality-adjusted life years
Figure 2 VIDAFACT participant
timeline.
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will be calculated as the area under the EQ-5D utility
curve. Since patients with missing values from question-
naires are likely to be worse than those with the available
measurements, the missing outcomes will be imputed
using non-linear regression models. A p<0.05 will be
established as statistically signiﬁcant. R software will be
used.42
ETHICS AND DISSEMINATION
Any amendment will be immediately communicated to
both agencies. All participants will provide signed
informed consent and their conﬁdentiality will be guar-
anteed by encoding all personal information. Insurance
will cover any unexpected damage attributable to partici-
pation in the study.
Ethical implications
An external Safety Monitoring Committee has been
created, comprised of one physician external to the
study from each of the participating hospitals. They will
be responsible for monitoring participants’ calcium and
vitamin D levels during the study in order to ensure the
patients’ safety and allocation concealment. The
research team has no economical interest in favour of or
against vitamin D supplementation. Its only interest is to
provide evidence as to whether vitamin D supplementa-
tion is beneﬁcial or not for patients with advanced
cancer in palliative care. Criteria to stop after any of the
two planned interim analyses are clearly stablished in
the study protocol. After each interim analysis, blindly
performed by the statistician of the research team, the
pharmacy service will assess the results of interim ana-
lyses in relation to the stopping rules established in the
protocol and with their exclusive knowledge of the inter-
vention groups. They will be responsible for communi-
cating the end or the continuation of the study based
on the criteria established in the study protocol to the
research team. The two interim analyses and the phase
II/III study design are part of this protocol to minimise
the use of time and patients required to demonstrate
whether, as hypothesised, there is a clinically signiﬁcant
beneﬁt from the use of vitamin D in patients with
advanced cancer in palliative care. The size of the group
randomly assigned to placebo is minimised during the
study and, if the effect of vitamin D interventions
become conclusive,this group will also be supplemented
with vitamin D.
Dissemination policy
Given this project’s scientiﬁc and social interest, its
results will be locally and internationally disseminated in
congresses, scientiﬁc papers and the media.
DISCUSSION
The potentially high scientiﬁc and social interests of this
project, fully based on the premise that ‘When no
curable treatment is possible, palliative care should be
directed towards minimizing symptoms, relieving suffer-
ing and bringing patient to the best possible health
related quality of life’, can be summarised as follows:
Scientiﬁcally:
1. The results of this safe, cost-effective intervention
with vitamin D supplementation in patients in pallia-
tive care research would be, to the best of our knowl-
edge, the ﬁrst attempt to conclusively address
whether the quality of life for these patients could
also improve from the prosurvival properties of a
normal vitamin D status, as reported not only in
healthy individuals but also in those with diabetes,
hypertension, cardiovascular disease, autoimmune
disorders, tuberculosis, kidney disease and cancer.
2. This work could provide evidence-based recommen-
dations for the efﬁcacy of vitamin D supplementation
to patients in palliative care in improving their
quality of life. Such a ﬁnding could be immediately
incorporated into clinical practice due to its low cost
and lack of toxicity. Furthermore, if conﬁrmed, these
ﬁndings should provide a solid basis for the design of
prospective, well-powered clinical trials directed at
customising vitamin D supplementation regimens in
order to expedite the correction of vitamin D deﬁ-
ciency in treatment-resistant patients and, more
importantly, ensure the fast improvement of their
quality of life.
3. It could help initiate new lines of research on the
pathogenesis of cancer-related fatigue to prevent its
onset at early stages and attenuate its progression in
cancer.
4. It could bring basic and clinical research together in
the arena of advanced cancer.
5. The most optimistic outcome would be to change the
‘current paradigm’ for patients in palliative care from
a state of ‘no curable treatment possible’ to a vitamin
D healing transition making the patient eligible for a
new customised cancer therapy with vitamin D as a
coadjuvant therapy.
Socially:
1. For the individual: The possibility of giving a patient
in palliative care a safe, non-costly, and evidence-
based effective option to maintain their quality of
life, and the hope that they could eventually become
eligible to restart cancer therapy for a cure is
invaluable.
2. For the community: This is research with a poten-
tially high clinical relevance, completely independent
from the interests of the pharmaceutical industry,
whose results could beneﬁt patients in palliative care
even in underdeveloped countries with the poorest
of healthcare systems.
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